Evidence map›Paper›PMID 28949786›Full record

ReviewHuman vaccines & immunotherapeutics2017

Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.

Chao Liu, Haiyan Gao, Peng Lv, Jingyi Liu, Gang Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. ExtracellularFrontiers in bioengineering and biotechnology · 2022
    Review
  8. Native and engineered extracellular vesicles for wound healing.Frontiers in bioengineering and biotechnology · 2022
    Review
  9. Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  10. Article
  11. EVs and Bioengineering: From Cellular Products to Engineered Nanomachines.International journal of molecular sciences · 2020
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chao Liua State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Mole-cular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen , China.
Haiyan Gaoa State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Mole-cular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen , China.
Peng Lva State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Mole-cular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen , China.
Jingyi Liua State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Mole-cular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen , China.
Gang Liua State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Mole-cular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen , China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are membrane-derived vesicles that are enriched with RNAs, proteins and other functional molecules. We exploit the unique physical properties of EVs as a promising and advantageous nanoplatform for the delivery of therapeutic drugs and genetic materials. Early successes in the discovery of various disease-related characteristics of EVs have driven a new wave of innovation in developing nanoscale drug-delivery systems (DDSs). Nevertheless, there are several issues that need to be considered during the development of these alternative DDSs, such as standardized isolation and preservation methods, efficient drug encapsulation, mechanisms of drug release and so on. In this mini-review, we summarize the current status and progress of EV-based DDSs as an efficient nanoplatform for therapeutics delivery, followed by a discussion on their challenges and future prospects for clinical translation and applications.

Indexed as

AnimalsDrug Delivery SystemsExtracellular VesiclesHumansMiceNanostructuresNanotechnologyNeoplasmsProteinsProteinscancerclinical translationdrug delivery systemextracellular vesicles

Identifiers

PMID28949786
PMCPMC5703411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.